Breath Biotics™

AOR08380

Probiotic breath freshener & oral hygiene*

  • Naturally sweetened with a fresh, minty taste
  • High dose of the patented oral probiotic strain BLIS™ K12
  • Clinically studied to promotes a healthy oral microbiome
  • Sugar free
Gluten Free
Non-GMO
Vegetarian

$34.96 or subscribe and save 20%

In stock

Choose a purchase plan:

AOR’s Breath Biotics™ formula with BLIS™ K12 contains a patented strain of the probiotic Streptococcus salivarius K12, which helps ensure healthy oral microflora, therefore reducing the bacteria that cause both bad breath and sore throat. An estimated one out of every four individuals experience halitosis regularly. There are several issues that may trigger bad breath with poor oral hygiene and the buildup of bacteria being at the top of the list. But bad breath may be the result of a number of other factors as well such as exposure to malodorous foods, an infection, or a deeper, more systemic medical concern.

Breath odor itself relates to volatile compounds with a high sulfur content that are produced by gram-negative bacteria on the tongue or between and around teeth. Halitosis can be transient (from sulfuric foods, tobacco products, or dry mouth) or it can persist. Cleaning the tongue, by brushing or with mouthwashes, may remove some of the offensive compounds (food remnants, dead cells, etc.) that the bacteria feed on. It may also clear away the bacteria themselves or help mask the odor for a period of time. Treatment of the underlying cause, however, is ultimately the best practice. When combating halitosis, the first step should be determining whether the oral microbiota are healthy.*

*Persistent halitosis may indicate a more serious condition and it is best to consult with a health care provider for a course of treatment.

AOR Advantage

AOR’s Breath Biotics™ offers the support needed to target the underlying cause of halitosis and promote clean and fresh breath with BLIS™ K12.

 

Discussion

Breath Biotics™ is Streptococcus salivarius K12, an oral probiotic which helps promote fresh breath and oral health.*

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, sesame seeds, sulfites, mustard, eggs or shellfish.

Directions

For oral health take one to two lozenges daily for a minimum of 10 days. Suck lozenge for five minutes, do not chew or swallow. Take at least two to three hours before or after antibiotics.

Cautions

Consult a health care provider before use if you are pregnant, lactating, have a medical condition, or are taking any medication. Keep out of reach of children.

Disclaimer

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Serving Size: One Lozenge / Servings Per Container: 60
Per Lozenge
Per Day (Two Lozenges)
Amount Per Serving
% Daily Value
% Daily Value
BLIS K12™
(Streptococcus salivarius K12)
20 mg
(1 BIL. CFU ‡)
40 mg (2 BIL. CFU ‡)

‡ CFU: Colony-forming units
† Daily Value not established.

Blis K12™ is a registered trademark of Blis Technologies New Zealand.

 

Other Ingredients: isomalt, maltodextrin, monk fruit extract, starch, hyprolose, trehalose, lacitol, natural flavor (wintergreen, peppermint) and sodium stearyl fumarate.

Contains: milk.

 

Burton, J.P., et al., A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol, 2006. 100(4): p. 754-64.

Burton, J. P., S. Cowley, et al. (2011). “Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study.” Food Chem Toxicol 49(9): 2356-2364.

Chilcott, C., et al., Elevated levels of interferon gamma in human saliva following ingestion of Streptococcus salivarius K12, in Joint New Zealand an Australian Microbiological Societies
Annual Meeting. 2005: Dunedin.

Dierksen, K. P., C. J. Moore, et al. (2007). “The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of
streptococcal populations on the tongue.” FEMS Microbiol Ecol 59(3): 584-591.

Dierksen, K. P., and J. Tagg. 2000. The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. p. 81-85. In D. R. Martin and T. J. (ed.), Streptococci and streptococcal diseases entering the new millennium. Securacopy, Auckland.

Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014 Feb 13;6:15-20. doi: 10.2147/DHPS.S59665. eCollection 2014.

Fantinato V, Jeorge AOA, Shimizu MT. 1999. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev. Microbiol. 30:332-34.

Kreth, J., Giacaman, R. A., Raghavan, R. and Merritt, J. (2016), The Road Less Traveled – Defining molecular commensalism with Streptococcus sanguinis. Mol oral Microbiol. Accepted Author Manuscript. doi:10.1111/omi.12170

Marchetti E, Tecco S, Santonico M, Vernile C, Ciciarelli D, Tarantino E, Marzo G, Pennazza G. Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)-Containing Lozenges–A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Sensors (Basel). 2015 Aug 10;15(8):19583-96. doi: 10.3390/s150819583.

Power DA, Burton JP, Chilcott CN, PJ Dawes and Tagg JR (2008) Preliminary Investigations of the Colonisation of Upper Respiratory Tract Tissues of Infants Using a Paediatric Formulation of the Oral Probiotic Streptococcus salivarius K12. European Journal of Clinical Microbiology & Infectious Diseases 27: 1261 -3.

Walls, T., D. Power, and J. Tagg, Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media. J Med Microbiol, 2003. 52(Pt 9): p. 829-33.

Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 Dec;7(12):1355-71. doi: 10.2217/fmb.12.113.

Wescombe, P. A., Upton, M., Dierksen, K. P., Ragland, N. L., Sivabalan, S., Wirawan, R. E., Inglis, M. A., Moore, C. J., Walker, G. V., Chilcott, C. N., Jenkinson, H. F., Tagg, J. R. (2006). Production of the Lantibiotic Salivaricin A and Its Variants by Oral Streptococci and Use of a Specific Induction Assay To Detect Their Presence in Human Saliva. Appl. Environ. Microbiol. 72: 1459- 1466

Please select a start rating
{{review.user_complete_name}}
{{review.date | date:'medium'}}
{{review.comment}}
Comment pending for approval
Reply
{{child.user_complete_name}}
{{child.date | date:'medium'}}
{{child.comment}}
Comment pending for approval
Reply
{{child2.user_complete_name}}
{{child2.date | date:'medium'}}
{{child2.comment}}
Comment pending for approval
Reply

You may also like…